| Study | n | Design | Study period / follow-up | Treatment arms | Effect on survival |
|---|---|---|---|---|---|
| ADT = androgen deprivation therapy; CSS = cancer-specific survival; EBRT = external beam radiotherapy in standard fractionation; FFS = failure-free survival; HR = hazard ratio; mo = months; n = number of patients; OS = overall survival; RP = radical prostatectomy; RT = radiotherapy; wk = week; yr = year. | |||||
| Bryant, et al., 2018 «Bryant AK, Kader AK, McKay RR ym. Definitive Radia...»1 |
648 | Retrospective (National Veterans Affairs) |
2000-2015 61 mo. |
ADT ± EBRT | Significant benefit for combined treatment only if PSA levels less than the median (26 ng/mL) All-cause mortality HR: 0.50 CSS, HR: 0.38 |
| Sarkar, et al., 2019 «Sarkar RR, Bryant AK, Parsons JK ym. Association b...»2 |
741 | Retrospective (National Veterans Affairs) |
2000-2015 51 mo. |
ADT ± local treatment (surgery or RT) |
Significant benefit for RP All-cause mortality HR 0.36 CSS, HR: 0.32 No statistical difference for RP vs. RT (p ≥ 0.1) All-cause mortality HR: 047 CSS, HR: 0.88 |
| Lin, et al., 2015 «Lin CC, Gray PJ, Jemal A ym. Androgen deprivation ...»3 |
983 before propensity score matching |
Retrospective (NCDB) |
2004-2006 48 mo. |
ADT ± EBRT | Significant benefit for combined treatment 5-yr. OS: 73% vs. 52% HR: 0.5 |
| Tward, et al., 2013 «Tward JD, Kokeny KE, Shrieve DC. Radiation therapy...»4 |
1,100 | Retrospective (SEER) |
1988-2006 64 mo. |
EBRT (n = 397) vs. no EBRT (n=703) No information on ADT) |
Significant benefit for EBRT 5-yr. CSS: 78% vs. 71% HR: 0.66 5-yr. OS: 68% vs. 56%, HR: 0.70 |
| Rusthoven,et al. 2014 «Rusthoven CG, Carlson JA, Waxweiler TV ym. The imp...»5 | 796 | Retrospective (SEER) |
1995-2005 61 mo. |
EBRT vs. no EBRT (no information on ADT) |
Significant benefit for EBRT 10-yr. OS: 45% vs. 29% HR: 0.58 |
| Seisen, et al., 2018 «Seisen T, Vetterlein MW, Karabon P ym. Efficacy of...»6 |
1,987 | Retrospective (NCDB) |
2003-2011 50 mo. |
ADT ± local treatment (surgery or RT) |
Significant benefit for combined treatment 5-yr. OS: 78.8% vs. 49.2% HR: 0.31 No difference between RP and RT |
| James, et al., 2016 «James ND, Spears MR, Clarke NW ym. Failure-Free Su...»7 |
177 | Unplanned subgroup analysis RCT |
2005-2014 17 mo. |
ADT ± EBRT | Significant benefit for combined treatment 5-yr OS: 93% vs. 71% 2-yr FFS: 81% vs. 53% FFS, HR: 0.48 |
| Elumalai et al. «Elumalai T, Maitre P, Portner R, ym. Impact of pro...»8 | 337 | Retrospective 4 centres UK | 2022-2019 | ADT +/- EBRT |
Significant benefit for combined treatment 5-yr. OS: 87% vs. 56% HR: 0.27 5-yr. BPFS: 74.1% vs. 34.2% HR: 0.33 |